ProShare Advisors LLC Increases Stock Holdings in Glaukos Co. (NYSE:GKOS)

ProShare Advisors LLC lifted its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 44.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,869 shares of the medical instruments supplier's stock after acquiring an additional 4,542 shares during the period. ProShare Advisors LLC's holdings in Glaukos were worth $2,229,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. IFP Advisors Inc purchased a new position in shares of Glaukos during the fourth quarter worth approximately $43,000. Asset Planning Inc purchased a new position in shares of Glaukos during the fourth quarter worth approximately $90,000. CoreCap Advisors LLC grew its position in Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after buying an additional 200 shares during the last quarter. Picton Mahoney Asset Management purchased a new position in Glaukos in the 4th quarter valued at $125,000. Finally, SBI Securities Co. Ltd. purchased a new position in Glaukos in the 4th quarter valued at $153,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of analyst reports. Piper Sandler lowered their price objective on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 15th. Mizuho lowered their price objective on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 16th. Wells Fargo & Company lowered shares of Glaukos from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $160.00 to $86.00 in a research report on Thursday, May 1st. Stephens lowered their price objective on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Finally, Stifel Nicolaus lowered their price objective on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, Glaukos presently has a consensus rating of "Moderate Buy" and an average target price of $134.67.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares of the company's stock, valued at $5,708,568.04. The trade was a 2.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 5.80% of the company's stock.

Glaukos Price Performance

Glaukos stock opened at $97.49 on Wednesday. Glaukos Co. has a one year low of $77.10 and a one year high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The business has a fifty day moving average of $93.78 and a two-hundred day moving average of $125.41. The company has a market cap of $5.57 billion, a P/E ratio of -33.97 and a beta of 0.83.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The company had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Glaukos's quarterly revenue was up 24.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.70) earnings per share. As a group, analysts predict that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co. (NYSE:GKOS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.